跳至主要内容
临床试验/NCT00136773
NCT00136773已完成4 期

Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus

Novartis0 个研究点目标入组 332 人开始时间: 2003年4月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Novartis
入组人数
332
主要终点
Change from baseline in the urine albumin/creatinine ratio after 52 weeks

研究概览

简要总结

Type 2 diabetes mellitus is usually associated with high blood pressure, which is a risk factor for kidney disease. Aggressive blood pressure reduction is an important strategy to protect the kidney and reduce urinary protein which develops with kidney disease. This study will evaluate the effects of amlodipine/benazepril in reducing blood pressure and urinary protein in hypertensive subjects with type 2 diabetes mellitus.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
21 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Mild to moderate hypertension
  • Type 2 diabetes mellitus
  • Presence of protein in the urine (albuminuria)

排除标准

  • Kidney disease not caused by diabetes or hypertension
  • Renal artery stenosis
  • Myocardial infarction or stroke within the last 6 months
  • Type 1 diabetes mellitus
  • Pregnant or lactating females
  • Cancer within the last 5 years

结局指标

主要结局

Change from baseline in the urine albumin/creatinine ratio after 52 weeks

次要结局

  • Percentage of patients who have progressed to diabetic kidney disease (urine albumin/creatinine ratio ≥ 300 µg/mg creatinine) after 52 weeks
  • Change from baseline in the ratio of urine albumin/creatinine ratio an estimate of kidney function after 52 weeks
  • Change from baseline in insulin resistance after 52 weeks
  • Change from baseline in urine albumin secretion after 52 weeks
  • Change from baseline in a marker of heart failure after 52 weeks

研究者

发起方
Novartis
申办方类型
Industry

相似试验